Last $39.39 USD
Change Today -0.67 / -1.68%
Volume 255.9K
ACOR On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 12:32 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (ACOR) Key Developments

Acorda Therapeutics, Inc. Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson’s Disease

Acorda Therapeutics, Inc. announced that the first patient has been enrolled in a Phase 3 study of CVT-301 for the treatment of OFF episodes in Parkinson's disease (PD). OFF episodes are characterized by a re-emergence of PD symptoms such as tremor, muscle stiffness and impaired ability to move. CVT-301 is a novel, self-administered inhaled therapy designed to provide rapid, reliable delivery of a precise dose of levodopa (L-dopa) through the lungs to return people with PD to an ON state. An ON state is when a patients symptoms are adequately controlled, allowing people with Parkinson's to more readily perform daily activities. The multi-center, double blind, randomized trial is expected to enroll approximately 345 participants across three arms: 50mg, 35mg, or placebo. These are the same doses used in the Phase 2b study. The primary outcome measure is improvement on the Unified Parkinson's Disease Rating Scale (UPDRS) Part III after administration of CVT-301.

Acorda Therapeutics, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 11:00 AM

Acorda Therapeutics, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 11:00 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Andrew R. Blight, Chief Scientific Officer, Michael W. Rogers, Chief Financial Officer and Principal Accounting Officer.

Acorda Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 09:20 AM

Acorda Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 09:20 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom. Speakers: Andrew R. Blight, Chief Scientific Officer.

Acorda Therapeutics, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 01:50 PM

Acorda Therapeutics, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 01:50 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Ron Cohen, Founder, Chief Executive Officer, President and Director.

Acorda Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Acorda Therapeutics, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $105,961,000 compared to $84,919,000 for the same period a year ago. Operating income was $20,829,000 compared to $11,372,000 for the same period a year ago. Income before income taxes was $16,489,000 compared to $10,990,000 for the same period a year ago. Net income was $11,953,000 or $0.28 per diluted share compared to $7,477,000 or $0.18 per diluted share for the same period a year ago. Non-GAAP net income was $27,569,000 or $0.65 per diluted share compared to $18,115,000 or $0.43 per diluted share for the same period a year ago. For the nine months, the company reported total revenues of $283,608,000 compared to $243,838,000 for the same period a year ago. Operating income was $35,223,000 compared to $17,618,000 for the same period a year ago. Income before income taxes was $30,703,000 compared to $16,235,000 for the same period a year ago. Net income was $17,342,000 or $0.41 per diluted share compared to $10,250,000 or $0.25 per diluted share for the same period a year ago. Non-GAAP net income was $54,099,000 or $1.28 per diluted share compared to $33,494,000 or $0.81 per diluted share for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACOR:US $39.39 USD -0.67

ACOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $31.99 USD -0.99
Avanir Pharmaceuticals Inc $16.92 USD +0.065
Depomed Inc $15.98 USD -0.26
Durect Corp $0.83 USD +0.02
Isis Pharmaceuticals Inc $62.48 USD -2.61
View Industry Companies
 

Industry Analysis

ACOR

Industry Average

Valuation ACOR Industry Range
Price/Earnings 72.0x
Price/Sales 4.4x
Price/Book 3.2x
Price/Cash Flow 71.4x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.